Holen Sie sich die Stockscreener-App
7.91
3.30%
-0.27
Vorhandelsmarkt:
6.70
-1.21
-15.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NEO?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$8.18
Offen:
$8.13
24-Stunden-Volumen:
1.99M
Relative Volume:
1.08
Marktkapitalisierung:
$1.03B
Einnahmen:
$727.33M
Nettoeinkommen (Verlust:
$-108.03M
KGV:
-9.372
EPS:
-0.844
Netto-Cashflow:
$-21.78M
1W Leistung:
-3.06%
1M Leistung:
-2.35%
6M Leistung:
-24.31%
1J Leistung:
-20.18%
1-Tages-Spanne:
$7.69
$8.255
1-Wochen-Bereich:
$7.69
$8.60
52-Wochen-Spanne:
$4.72
$13.74
Neogenomics Inc Stock (NEO) Company Profile
Firmenname
Neogenomics Inc
Sektor
Branche
Telefon
(239) 768-0600
Adresse
9490 NEOGENOMICS WAY, FORT MYERS, FL
Compare NEO vs TMO, DHR, IDXX, A, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NEO
Neogenomics Inc
|
7.91 | 1.04B | 727.33M | -108.03M | -21.78M | -0.844 |
TMO
Thermo Fisher Scientific Inc
|
466.70 | 194.94B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
178.57 | 137.69B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
560.93 | 45.19B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.42 | 34.50B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
311.20 | 32.91B | 3.17B | 642.63M | 516.49M | 10.77 |
Neogenomics Inc Stock (NEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Herabstufung | BTIG Research | Buy → Neutral |
| 2025-07-29 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-05-15 | Eingeleitet | Guggenheim | Neutral |
| 2025-04-30 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-01-13 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2024-12-10 | Eingeleitet | Jefferies | Buy |
| 2024-05-01 | Fortgesetzt | Craig Hallum | Buy |
| 2023-12-29 | Bestätigt | BTIG Research | Buy |
| 2023-08-21 | Hochstufung | Stephens | Equal-Weight → Overweight |
| 2023-05-16 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-05-09 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-02-24 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2023-02-01 | Hochstufung | Needham | Hold → Buy |
| 2022-08-26 | Herabstufung | The Benchmark Company | Buy → Hold |
| 2022-08-22 | Herabstufung | Needham | Buy → Hold |
| 2022-06-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-03-29 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-29 | Herabstufung | Stephens | Overweight → Equal-Weight |
| 2022-01-18 | Fortgesetzt | Stephens | Overweight |
| 2021-12-16 | Eingeleitet | Cowen | Outperform |
| 2021-11-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-06-03 | Eingeleitet | Goldman | Buy |
| 2021-02-25 | Fortgesetzt | Needham | Buy |
| 2021-02-25 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-01-28 | Eingeleitet | Truist | Buy |
| 2020-12-11 | Fortgesetzt | BTIG Research | Buy |
| 2020-10-28 | Bestätigt | Needham | Buy |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-08-28 | Eingeleitet | Guggenheim | Buy |
| 2020-07-29 | Bestätigt | Needham | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Buy |
| 2020-04-21 | Fortgesetzt | Stephens | Overweight |
| 2020-03-02 | Fortgesetzt | Craig Hallum | Buy |
| 2020-02-28 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2020-01-23 | Herabstufung | First Analysis Sec | Strong Buy → Outperform |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-05-01 | Bestätigt | Needham | Buy |
| 2019-03-29 | Bestätigt | Needham | Buy |
| 2019-01-03 | Eingeleitet | Needham | Buy |
| 2018-10-24 | Hochstufung | First Analysis Sec | Outperform → Strong Buy |
| 2018-08-21 | Eingeleitet | Leerink Partners | Outperform |
| 2018-05-02 | Herabstufung | First Analysis Sec | Overweight → Equal-Weight |
| 2017-09-11 | Herabstufung | BTIG Research | Buy → Neutral |
| 2017-08-24 | Eingeleitet | Gabelli & Co | Buy |
| 2016-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Neogenomics Inc Aktie (NEO) Neueste Nachrichten
NeoGenomics Expands Access to Full Oncology Testing Portfolio Through Epic Aura Integration - PharmiWeb.com
NeoGenomics, Inc. Expands Oncology Testing Portfolio Access Through Epic Aura Integration - marketscreener.com
NeoGenomics integrates testing portfolio with Epic Aura EHR - Investing.com
NeoGenomics Expands Oncology Testing Access With Epic Aura EHR Integration - citybiz
Is NeoGenomics (NEO) stock showing signs of reversal | Q4 2025: EPS Exceeds ExpectationsWall Street Views - Cổng thông tin điện tử tỉnh Lào Cai
NEO NeoGenomics posts 53.5 percent EPS beat in Q4 2025, yet shares drop 1.8 percent in today’s trading. - Cổng thông tin điện tử Tỉnh Sơn La
Earnings Preview: NeoGenomics to Report Financial Results Post-market on April 28 - Moomoo
NeoGenomics (NEO) Projected to Post Earnings on Tuesday - MarketBeat
NeoGenomics Inc stock (US64049M2098): Why does its oncology testing model matter more now? - AD HOC NEWS
NeoGenomics (NEO) Meets Q2 Earnings Estimates - MSN
NeoGenomics, Inc. Experiences Evaluation Revision Amidst Market Performance Challenges - Markets Mojo
Is NeoGenomics (NEO) stock forming lower lows (Bullish Momentum) 2026-04-18Low Risk Entry - Cổng thông tin điện tử tỉnh Tây Ninh
NeoGenomics (NASDAQ:NEO) Stock Price Down 5.3%Here's What Happened - MarketBeat
NeoGenomics to Spotlight AI-Driven Genomic–Clinical Data Integration at AACR 2026 - Clinical Lab Products
NeoGenomics, Inc. (NASDAQ:NEO) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
Will NeoGenomics Inc outperform the market in YEAR2026 Earnings Impact & Community Shared Stock Ideas - baoquankhu1.vn
A Look Back at Testing & Diagnostics Services Stocks’ Q4 Earnings: NeoGenomics (NASDAQ:NEO) Vs The Rest Of The Pack - Yahoo Finance
Guidance Update: Can NeoGenomics Inc deliver alpha2026 Chart Watch & Verified Momentum Stock Watchlist - baoquankhu1.vn
NeoGenomics to Present Multiple Abstracts Showcasing New Research at AACR Annual Meeting 2026 - National Today
Bearish Setup: Will NeoGenomics Inc stock hit new highs in YEAR2026 Historical Comparison & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Buybacks Report: Why is NeoGenomics Inc stock going up2026 Price Swings & Safe Swing Trade Setups - baoquankhu1.vn
Setup Watch: Can NeoGenomics Inc keep up with sector leaders2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Tudor Investment Corp ET AL Trims NeoGenomics, Inc. $NEO Stake - National Today
NeoGenomics, Inc. $NEO Stake Trimmed by Tudor Investment Corp ET AL - MarketBeat
Published on: 2026-04-09 16:25:20 - baoquankhu1.vn
NeoGenomics, Inc. (NASDAQ: NEO) Q4 2025 earnings call transcript - MSN
NeoGenomics to Report First Quarter 2026 Financial Results on April 28, 2026 - BioSpace
NeoGenomics to Report Q1 2026 Earnings on April 28 - National Today
NeoGenomics, Inc. (NEO) Stock forecasts - Yahoo Finance UK
NEOGENOMICS INC ($NEO) CEO 2025 Pay Revealed - Quiver Quantitative
NeoGenomics (NASDAQ: NEO) seeks approval to expand 2023 equity incentive plan - Stock Titan
Aberdeen Group plc Buys 1,006,676 Shares of NeoGenomics, Inc. $NEO - MarketBeat
NeoGenomics | DEF 14A: Definitive information statements - Moomoo
NeoGenomics (NEO) COO nets shares after 17,562-unit RSU vesting - Stock Titan
NeoGenomics (NEO) CEO exercises RSUs and uses shares to cover taxes - Stock Titan
NeoGenomics Inc stock: Precision oncology leader facing growth hurdles - AD HOC NEWS
NeoGenomics, Inc. (NEO) stock price, news, quote and history - Yahoo Finance UK
NeoGenomics Inc Stock: Precision Oncology Leader Faces Growth Challenges in Competitive Diagnostics - AD HOC NEWS
NEO|Neogenomics Inc|Price:7.995|Chg%:-0.00 - TradingKey
Growth Value: Why is NeoGenomics Inc stock going upWeekly Market Outlook & Capital Efficient Trade Techniques - baoquankhu1.vn
Geopolitics Watch: Will NeoGenomics Inc outperform the market in YEAR2026 Intraday Action & Community Consensus Trade Signals - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (NEO) Movement - Stock Traders Daily
NeoGenomics Inc Stock: A Key Player in Cancer Diagnostics Amid Evolving Healthcare Demands - AD HOC NEWS
Loss Report: Should you buy the dip on NeoGenomics Inc2026 Summary & Consistent Return Investment Signals - baoquankhu1.vn
NeoGenomics Q2 2025 Earnings Preview - MSN
Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc. - National Today
Tudor Investment Corp ET AL Sells 320,361 Shares of NeoGenomics, Inc. $NEO - MarketBeat
GRI Bio (NASDAQ:GRI) versus NeoGenomics (NASDAQ:NEO) Financial Contrast - Defense World
Vanguard files 13G/A: NeoGenomics (NEO) ownership shows 0 shares - Stock Titan
Dip Buying: Whats the analyst consensus on NeoGenomics Inc2026 Selloffs & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
NeoGenomics invites engagement on innovation in oncology at USCAP event - Traders Union
Finanzdaten der Neogenomics Inc-Aktie (NEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):